Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin cofactor II deficiency.

Douglas M Tollefsen1

  • 1Hematology Division, Department of Medicine, Washington University School of Medicine, St Louis, Mo 63110, USA. tollefsen@im.wustl.edu

Archives of Pathology & Laboratory Medicine
|November 8, 2002
PubMed
Summary

Congenital heparin cofactor II deficiency is not recommended for testing in patients with thromboembolic disease due to insufficient evidence. Further research is needed to establish its role as a thrombotic risk factor.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

α2β1 integrin, GPVI receptor, and common FcRγ chain on mouse platelets mediate distinct responses to collagen in models of thrombosis.

PloS one·2014
Same author

Proteolytic activation transforms heparin cofactor II into a host defense molecule.

Journal of immunology (Baltimore, Md. : 1950)·2013
Same author

The collection of NFATc1-dependent transcripts in the osteoclast includes numerous genes non-essential to physiologic bone resorption.

Bone·2012
Same author

Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis.

Thrombosis research·2011
Same author

Inhibition of antithrombin by Plasmodium falciparum histidine-rich protein II.

Blood·2011
Same author

Dermatan sulfate and bone marrow mononuclear cells used as a new therapeutic strategy after arterial injury in mice.

Cytotherapy·2011

Area of Science:

  • Hematology
  • Thrombosis Research
  • Diagnostic Medicine

Background:

  • Congenital heparin cofactor II deficiency is a rare inherited disorder.
  • Its role as a risk factor for thrombosis requires further investigation.
  • Current diagnostic approaches for thrombophilia need evaluation.

Purpose of the Study:

  • To review the current literature on heparin cofactor II deficiency and thrombosis.
  • To establish expert consensus on the diagnostic utility of heparin cofactor II deficiency testing.
  • To provide recommendations for laboratory assay use in assessing thrombotic risk.

Main Methods:

  • Comprehensive review of the medical literature from the past decade.
  • Expert consensus development at the College of American Pathologists Conference XXXVI.
  • Critical assessment of clinical study design and laboratory methodologies.

Main Results:

  • The literature review did not provide sufficient evidence to link heparin cofactor II deficiency to increased thrombotic risk.
  • Expert consensus confirmed the lack of data supporting routine testing for this deficiency.
  • Current laboratory assays are not recommended for this specific diagnostic purpose.

Conclusions:

  • There is insufficient evidence to recommend testing for congenital heparin cofactor II deficiency in patients presenting with thromboembolic disease.
  • The clinical significance of heparin cofactor II deficiency as a thrombotic risk factor remains unproven.
  • Further research is warranted to clarify the association between heparin cofactor II deficiency and thrombosis.

Related Experiment Videos